Efficacy and Tolerability of Temozolomide in an Alternating Weekly Regimen in Patients With Recurrent Glioma

Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma

2005 • 18,835 citations

Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.

1996 • 5,667 citations

Response criteria for phase II studies of supratentorial malignant glioma.

1990 • 2,401 citations

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

2000 • 940 citations

Outcomes and Prognostic Factors in Recurrent Glioma Patients Enrolled Onto Phase II Clinical Trials

1999 • 911 citations

What's going on 放射線 Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. N Engl J Med. 2005; 352: 987-96. PMID: 15758009.--神経膠腫に対する治療として、放射線治療とテモゾロマイドの併用が世界的な標準的治療となりうることを示唆する論文

2006 • 783 citations

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

2003 • 365 citations

Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors

2004 • 271 citations

Randomized Phase II Study of Temozolomide and Radiotherapy Compared With Radiotherapy Alone in Newly Diagnosed Glioblastoma Multiforme

2005 • 264 citations

Selective CD4⁺ Lymphopenia in Melanoma Patients Treated With Temozolomide: A Toxicity With Therapeutic Implications

2004 • 259 citations

Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO)

2006 • 227 citations

Correlation Between O⁶-Methylguanine-DNA Methyltransferase and Survival in Inoperable Newly Diagnosed Glioblastoma Patients Treated With Neoadjuvant Temozolomide

2007 • 203 citations

Analysis of p53 Mutation and Epidermal Growth Factor Receptor Amplification in Recurrent Gliomas with Malignant Progression

1996 • 174 citations

Phase II Trial of Lomustine Plus Temozolomide Chemotherapy in Addition to Radiotherapy in Newly Diagnosed Glioblastoma: UKT-03

2006 • 160 citations

One week on/one week off: A novel active regimen of temozolomide for recurrent glioblastoma

2004 • 157 citations

Neuro-Oncology Working Group 01 Trial of Nimustine Plus Teniposide Versus Nimustine Plus Cytarabine Chemotherapy in Addition to Involved-Field Radiotherapy in the First-Line Treatment of Malignant Glioma

2003 • 139 citations

Salvage temozolomide for prior temozolomide responders

2005 • 84 citations

Is protracted low-dose temozolomide feasible in glioma patients?

2006 • 37 citations

Predicting the extent of invasive disease by MRI to enhance the use of minimally invasive techniques in the management of early stage breast carcinoma

2004 • 23 citations

Pharmacodynamic study of skin biopsy specimens in patients (pts) with refractory or advanced malignancies following administration of AP23573, an mTOR inhibitor

2005 • 18 citations

A phase II study of temozolomide administered 21 out of 28 days for the treatment of patients with recurrent anaplastic (oligo) astrocytoma: An interim analysis of toxicity

2005 • 3 citations

Deleted Work

1955 • 0 citations